Physician profile
Michael L Chou
NPI 1134323363
$9,083.41
in general payments reported to CMS, 2019-2025
29 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $1,200 · 2021: $1,568 · 2022: $1,321 · 2023: $1,430 · 2024: $1,227 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269 · Education: $80.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.84 |
| Education | $80.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,724.86 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,127.47 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $952.73 | 2019-2025 | Dupixent |
| Genzyme Corporation | $706.28 | 2019-2025 | |
| Optinose US, INC. | $400.99 | 2019-2025 | |
| Pfizer INC. | $335.68 | 2019-2023 | |
| Kaleo, INC. | $227.13 | 2019-2024 | Auvi-Q |
| Organon LLC | $219.02 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $173.36 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.82 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $162.77 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $143.50 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $109.25 | 2020-2023 | |
| Genentech USA, INC. | $86.52 | 2019-2021 | |
| Alk-Abello, INC | $73.14 | 2020-2023 | Odactra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $71.24 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $57.21 | 2024 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $48.92 | 2021-2025 | Elaprase |
| Octapharma USA, INC. | $41.88 | 2020 | |
| Grifols USA, LLC | $40.40 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $35.36 | 2021 | |
| Circassia INC. | $30.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.35 | 2019 | |
| Galderma Laboratories, L.P. | $23.37 | 2025 | Nemluvio |
| Aytu Biopharma, INC. | $23.20 | 2025 | |
| Merck Sharp & Dohme LLC | $20.22 | 2021 | |
| Aimmune Therapeutics, INC. | $19.64 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.16 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $15.26 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.